International Journal of Women's Health and Reproduction Sciences

Home Aim and Scope Instructions to Authors Editorial Policies Editorial Board Authorship Agreement Form Open Access and Copyright

Jul 2024, Vol 12, Issue 3

CURRENT ISSUE ARCHIVE AHEAD OF PRINT / ACCEPTED ARTICLE MOST VIEWED ARTICLES NEWS RELATED LINKS

Advanced Search

For Author's & Reviewer's

Committee on Publication
Ethics (COPE) Flowchart

Recommendations for the Conduct

COPE: Reviewers

World Association of Medical Editors(WAME)

EQUATOR Resources : Reviewers

Poll

How do you find the scientific quality of the published articles on our web site?

Very good

Good

Fair

Bad

Very bad

Original Article
Effect of Tranexamic Acid on Intra- and Postoperative Bleeding Ratio and Complications in Placenta Accreta Syndrome: A Double-Blind Clinical Trial
Kobra Shojaei¹, Mahin Najafian¹, Maryam Saberi Behbahani², Reza Akhondzadeh³
¹Department of Obstetrics and Gynecology, Faculty of Medicine, Fertility, Infertility and Fetal Health Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran ²Department of Obstetrics and Gynecology, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran ³Department of Anesthesiology, Faculty of Medicine, Pain Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
IJWHR 2024; 12: 136–141 DOI: 10.15296/ijwhr.2023.41 Viewed : 4473 times Downloaded : 3742 times. Keywords : Placenta accreta, Tranexamic acid, Cesarean section, Hemorrhage
Full Text(PDF) \| Related Articles
Abstract

Objectives: Placenta accreta syndrome (PAS) is one of the main problems of women during childbirth, also the most important cause of maternal morbidity and mortality. Tranexamic acid (TXA) is widely used to reduce blood loss and deaths due to bleeding in trauma patients and patients with postpartum hemorrhage. This study aimed to investigate the effect of TXA in reducing bleeding and complications during and after surgery in women with PAS. Materials and Methods: This double-blind clinical trial was performed on 46 women who underwent cesarean section with PAS diagnosis. The participants were randomly assigned in two groups (n=23/each): the TXA group received 1 g TXA intravenously and the control group received 50 mL of normal saline immediately after the surgery. Then, the postoperative estimated blood loss (EBL), amount of blood products transfusion, complications during and after delivery, including the need for hysterectomy, duration of hospitalization, and the number of days staying in the intensive care unit (ICU) were compared between the two groups. Results: The mean EBL during and after surgery in the TXA group was significantly lower than the control group (P < 0.0001). The TXA group received fewer blood products, including packed red blood cells (PRBCs), fresh frozen plasma (FFP), and platelet. The duration of surgery, duration of hospitalization, and the number of days in the ICU were significantly lower in the TXA group (P < 0.001). Hysterectomy was observed in 10 participants of the TXA group and 13 women in the control group, but the difference was not significant (P = 0.556). Conclusions: TXA administration effectively reduced postpartum hemorrhage, the need for postpartum blood transfusion, the duration of surgery, and the duration of hospitalization in women with PAS. TXA is a practical, inexpensive, safe, and readily available treatment and can be recommended as a prophylactic intervention to prevent blood loss in women with PAS. Trial Registration: https://www.irct.ir/, identifier: IRCT20201003048909N1.